Fowble B, Glick J, Goodman R
Dept. of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104.
Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):627-31. doi: 10.1016/0360-3016(88)90304-5.
From 1977 to 1986, 63 patients at high risk for isolated local-regional recurrence following mastectomy and adjuvant chemotherapy received post-operative radiotherapy. All patients had operable primary tumors (T1-3a). For entire group the mean and median number of positive nodes were 10 and 8, respectively. Radiotherapy consisted of 4500 to 5000 rad to the chest wall and regional nodes. Chemotherapy consisted of CMF +/- prednisone (45 patients), CAF (16 patients), and other variable regimens (2 patients). Relapse occurred in 23 patients with only two patients experiencing an isolated local-regional recurrence. In 3 patients local-regional recurrence appeared simultaneously with or following distant metastases and in 18 patients the pattern of failure was distant metastases alone. With a median follow-up of 28 months (range 9-87 mo.), 40 patients are alive without disease, 9 are alive with disease, and 14 have died with disease. The 4-year actuarial overall survival is 67% and the 4-year actuarial disease-free survival is 47%. The 4-year actuarial probability of an isolated local-regional recurrence is 5%. Complications related to the radiation included a 9% incidence of moderate to severe arm edema. This study demonstrates the ability of radiation to reduce the incidence of local-regional recurrence in a previously identified high risk group of patients and has produced encouraging survival results with minimal morbidity.
1977年至1986年期间,63例乳房切除术后接受辅助化疗且有孤立性局部区域复发高风险的患者接受了术后放疗。所有患者均有可手术切除的原发性肿瘤(T1 - 3a)。整个研究组阳性淋巴结的平均数和中位数分别为10个和8个。放疗包括对胸壁和区域淋巴结给予4500至5000拉德的剂量。化疗方案包括CMF ± 泼尼松(45例患者)、CAF(16例患者)以及其他可变方案(2例患者)。23例患者出现复发,其中仅2例发生孤立性局部区域复发。3例患者局部区域复发与远处转移同时出现或在远处转移之后出现,18例患者的复发模式仅为远处转移。中位随访时间为28个月(范围9 - 87个月),40例患者无病存活,9例患者带瘤存活,14例患者因病死亡。4年精算总生存率为67%,4年无病生存率为47%。孤立性局部区域复发的4年精算概率为5%。与放疗相关的并发症包括9%的患者出现中度至重度手臂水肿。本研究证明了放疗能够降低先前确定的高风险患者组中局部区域复发的发生率,并产生了令人鼓舞的生存结果,且发病率最低。